Lifecare ASA, a MedTech company developing next-generation continuous glucose
monitoring (CGM) technology, will hold an Extraordinary General Meeting on 12
November 2025 at 16:00 (CET).
Reference is made to the contemplated partially underwritten rights issue
announced by the Company on 22 October 2025, with gross proceeds of minimum
NOK 80 million and up to NOK 100 million (the "Rights Issue").
In order to facilitate the subscription of shares and exercise of warrants in
connection with the Rights Issue, the Board proposes that the General Meeting
resolves to reduce the par value of the Company's shares to NOK 0.10.
The meeting will be conducted as a combined physical and digital meeting.
Shareholders who wish to participate and vote at the Extraordinary General
Meeting must be registered with a user profile in the meeting portal Orgbrain
(www.orgbrain.no (http://www.orgbrain.no/)). Attendance will be possible
either in person or digitally through Orgbrain.
The notice with the complete agenda and supporting documents is available
at https://lifecare.no/events/
(https://eur04.safelinks.protection.outlook.com/?url=https%3A%2F%2Flifecare.no%2Fevents%2F&data=05%7C02%7Casle.wingsternes%40lifecare.no%7C4a63265cf098488ebb4108dc6ab305d6%7Cc5fbb1c64eb045db9f3c6e20ebcd710e%7C0%7C0%7C638502564358975745%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=99J503JrUH0aFS3zfd5ELtDtcVQ%2BKNmiUEwrqgZWN8k%3D&reserved=0).
About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring ("CGM") systems to market.
Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor
technology is suitable for identifying and monitoring the occurrence of a wide
range of analytes and molecules in the human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42
This information is subject to disclosure under the Norwegian Securities
Trading Act, ยง5-12. The information was submitted for publication at
2025-10-22 14:00 CEST.